The uptake and intracellular metabolism of 4-(1-pyrene)butanoic acid (P4), 10-(1-pyrene)decanoic acid (P10) and 12-(1-pyrene)dodecanoic acid (P12) were investigated in cultured lymphoid cell lines from normal individuals and from a patient with multisystemic lipid storage myopathy (MLSM). The cellular uptake was shown to be dependent on the fatty-acid chain length, but no significant difference in the uptake of pyrene fatty acids was observed between MLSM and control lymphoid cells. After incubation for 1 h the distribution of fluorescent fatty acids taken up by the lymphoid cell lines also differed with the chain length, most of the fluorescence being associated with phospholipid and triacylglycerols. In contrast with P10 and P12, P4 was not incorporated into neutral lipids. When the cells were incubated for 24 h with the pyrene fatty acids, the amount of fluorescent lipids synthesized by the cells was proportional to the fatty acid concentration in the culture medium. After a 24 h incubation in the presence of P10 or P12, at any concentration, the fluorescent triacylglycerol content of MLSM cells was 2-5-fold higher than that of control cells. Concentrations of pyrene fatty acids higher than 40 microM seemed to be more toxic for mutant cells than for control cells. This cytotoxicity was dependent on the fluorescent-fatty-acid chain length (P12 greater than P10 greater than P4). Pulse-chase experiments permitted one to demonstrate the defect in the degradation of endogenously biosynthesized triacylglycerols in MLSM cells (residual activity was around 10-25% of controls on the basis of half-lives and initial rates of P10- or P12-labelled-triacylglycerol catabolism); MLSM lymphoid cells exhibited a mild phenotypic expression of the lipid storage (less severe than that observed in fibroblasts). P4 was not utilized in the synthesis of triacylglycerols, and thus did not accumulate in MLSM cells: this suggests that natural short-chain fatty acids might induce a lesser lipid storage in this disease.
Skip Nav Destination
Follow us on Twitter @Biochem_Journal
Article navigation
July 1990
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkAdvertising
Research Article|
July 01 1990
Influence of chain length of pyrene fatty acids on their uptake and metabolism by Epstein–Barr-virus-transformed lymphoid cell lines from a patient with multisystemic lipid storage myopathy and from control subjects
J Radom;
J Radom
1Laboratoire de Biochimie, Faculté de Médecine-Rangueil, avenue J. Poulhès, 31054 Toulouse Cédex, France.
Search for other works by this author on:
R Salvayre;
R Salvayre
1Laboratoire de Biochimie, Faculté de Médecine-Rangueil, avenue J. Poulhès, 31054 Toulouse Cédex, France.
Search for other works by this author on:
T Levade;
T Levade
1Laboratoire de Biochimie, Faculté de Médecine-Rangueil, avenue J. Poulhès, 31054 Toulouse Cédex, France.
Search for other works by this author on:
L Douste-Blazy
L Douste-Blazy
1Laboratoire de Biochimie, Faculté de Médecine-Rangueil, avenue J. Poulhès, 31054 Toulouse Cédex, France.
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© 1990 London: The Biochemical Society
1990
Biochem J (1990) 269 (1): 107–113.
Citation
J Radom, R Salvayre, T Levade, L Douste-Blazy; Influence of chain length of pyrene fatty acids on their uptake and metabolism by Epstein–Barr-virus-transformed lymphoid cell lines from a patient with multisystemic lipid storage myopathy and from control subjects. Biochem J 1 July 1990; 269 (1): 107–113. doi: https://doi.org/10.1042/bj2690107
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() View past webinars > |